Gan & Lee Pharmaceuticals. (SHA:603087)
China
· Delayed Price · Currency is CNY 45.21
+0.23 (0.51%)
Apr 24, 2025, 2:45 PM CST
SHA:603087 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 1,059 | 902.78 | 2,443 | 2,890 | 3,306 | 2,825 | Upgrade
|
| Short-Term Investments | - | - | - | 201.36 | 276.44 | 945.34 | Upgrade
|
| Trading Asset Securities | 1,298 | 1,500 | 2,410 | 1,636 | 1,624 | 787.05 | Upgrade
|
| Cash & Short-Term Investments | 2,357 | 2,403 | 4,853 | 4,728 | 5,206 | 4,557 | Upgrade
|
| Cash Growth | -51.91% | -50.48% | 2.66% | -9.20% | 14.24% | 161.44% | Upgrade
|
| Accounts Receivable | 339.49 | 246.72 | 385.37 | 189.57 | 934.66 | 827.35 | Upgrade
|
| Other Receivables | 3.11 | 1.85 | - | 0.99 | 0.16 | 0.96 | Upgrade
|
| Receivables | 342.6 | 248.57 | 385.37 | 190.55 | 934.82 | 828.3 | Upgrade
|
| Inventory | 1,113 | 1,053 | 860.51 | 648.65 | 651.33 | 493.48 | Upgrade
|
| Other Current Assets | 88.08 | 86.11 | 76.73 | 97.36 | 77.95 | 80.55 | Upgrade
|
| Total Current Assets | 3,900 | 3,791 | 6,176 | 5,664 | 6,870 | 5,960 | Upgrade
|
| Property, Plant & Equipment | 3,878 | 3,882 | 3,886 | 3,661 | 2,595 | 2,149 | Upgrade
|
| Long-Term Investments | 547.19 | 508.74 | 334.66 | 30 | 201.36 | 466.05 | Upgrade
|
| Other Intangible Assets | 266.66 | 273.06 | 278.08 | 293.48 | 295.99 | 238.92 | Upgrade
|
| Long-Term Deferred Tax Assets | 213.85 | 206.94 | 168.95 | 138.25 | 30.8 | 14.93 | Upgrade
|
| Long-Term Deferred Charges | 1,052 | 924.91 | 821.97 | 743.19 | 588.87 | 544.27 | Upgrade
|
| Other Long-Term Assets | 2,427 | 2,456 | 49.99 | 76.51 | 270.33 | 134.67 | Upgrade
|
| Total Assets | 12,284 | 12,043 | 11,715 | 10,607 | 10,853 | 9,507 | Upgrade
|
| Accounts Payable | 112.92 | 129.13 | 94.82 | 36.52 | 26.15 | 14.79 | Upgrade
|
| Accrued Expenses | 167.43 | 150.68 | 192.54 | 190 | 173.04 | 183.07 | Upgrade
|
| Current Portion of Long-Term Debt | 8.4 | 10.06 | - | - | - | - | Upgrade
|
| Current Portion of Leases | - | - | 2.18 | 5.69 | 5.07 | - | Upgrade
|
| Current Income Taxes Payable | 11.84 | 11.19 | 1.42 | 1.35 | 106.32 | 53.35 | Upgrade
|
| Current Unearned Revenue | 54.03 | 63.25 | 52.99 | 68.13 | 36.56 | 68.44 | Upgrade
|
| Other Current Liabilities | 438.6 | 436.82 | 429.49 | 511.36 | 138.39 | 90.19 | Upgrade
|
| Total Current Liabilities | 793.21 | 801.13 | 773.45 | 813.04 | 485.53 | 409.85 | Upgrade
|
| Long-Term Leases | 3.06 | 3.31 | 5.45 | 8.33 | 12.17 | - | Upgrade
|
| Long-Term Unearned Revenue | 168.83 | 168.92 | 179.63 | 187.63 | 141.98 | 125.77 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 4.56 | 12.11 | - | - | 36.15 | 31.78 | Upgrade
|
| Other Long-Term Liabilities | 2.65 | 2.97 | 14 | 12.27 | 10.2 | 1.69 | Upgrade
|
| Total Liabilities | 972.31 | 988.45 | 972.52 | 1,021 | 686.02 | 569.09 | Upgrade
|
| Common Stock | 601.07 | 601.07 | 594.16 | 565.65 | 561.54 | 561.54 | Upgrade
|
| Additional Paid-In Capital | 3,611 | 3,591 | 3,351 | 2,563 | 2,476 | 2,474 | Upgrade
|
| Retained Earnings | 7,371 | 7,059 | 6,865 | 6,525 | 7,133 | 5,905 | Upgrade
|
| Treasury Stock | -275.64 | -200.85 | -71.36 | -71.36 | - | - | Upgrade
|
| Comprehensive Income & Other | 4.38 | 4.04 | 3.82 | 3.44 | -3.44 | -1.55 | Upgrade
|
| Total Common Equity | 11,312 | 11,054 | 10,743 | 9,586 | 10,167 | 8,939 | Upgrade
|
| Minority Interest | - | - | 0 | -0.16 | -0.16 | -0.16 | Upgrade
|
| Shareholders' Equity | 11,312 | 11,054 | 10,743 | 9,586 | 10,167 | 8,938 | Upgrade
|
| Total Liabilities & Equity | 12,284 | 12,043 | 11,715 | 10,607 | 10,853 | 9,507 | Upgrade
|
| Total Debt | 11.46 | 13.36 | 7.62 | 14.01 | 17.24 | - | Upgrade
|
| Net Cash (Debt) | 2,345 | 2,390 | 4,846 | 4,714 | 5,189 | 4,557 | Upgrade
|
| Net Cash Growth | -52.10% | -50.68% | 2.80% | -9.16% | 13.86% | 161.44% | Upgrade
|
| Net Cash Per Share | 3.99 | 4.04 | 8.55 | 8.37 | 9.25 | 8.55 | Upgrade
|
| Filing Date Shares Outstanding | 588.53 | 573.74 | 590.05 | 561.54 | 561.54 | 561.54 | Upgrade
|
| Total Common Shares Outstanding | 588.53 | 573.74 | 590.05 | 561.54 | 561.54 | 561.54 | Upgrade
|
| Working Capital | 3,107 | 2,990 | 5,402 | 4,851 | 6,385 | 5,550 | Upgrade
|
| Book Value Per Share | 19.22 | 19.27 | 18.21 | 17.07 | 18.11 | 15.92 | Upgrade
|
| Tangible Book Value | 11,045 | 10,781 | 10,464 | 9,292 | 9,871 | 8,700 | Upgrade
|
| Tangible Book Value Per Share | 18.77 | 18.79 | 17.73 | 16.55 | 17.58 | 15.49 | Upgrade
|
| Buildings | - | - | 1,367 | 1,165 | 1,046 | 1,013 | Upgrade
|
| Machinery | - | - | 1,474 | 1,237 | 1,263 | 1,171 | Upgrade
|
| Construction In Progress | - | - | 2,007 | 2,003 | 874.91 | 410.12 | Upgrade
|
Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.